NASDAQ: ASTHAstrana Health Inc Stock
$35.17+1.81 (+5.43%)
Updated Jan 17, 2025
ASTH Price
$35.17
Fair Value Price
$85.64
Market Cap
$1.98B
52 Week Low
$29.08
52 Week High
$63.20
P/E
26.85x
P/B
2.81x
P/S
1.89x
PEG
1.33x
Dividend Yield
N/A
Revenue
$1.72B
Earnings
$62.46M
Gross Margin
15.1%
Operating Margin
6.9%
Profit Margin
3.6%
Debt to Equity
1.11
Operating Cash Flow
$82M
Beta
1.22
Next Earnings
Feb 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ASTH Overview
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ASTH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
D
Momentum
C
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
ASTH
Ranked#36 of 45
Ranked#36 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.84 | A | |
| $98.65 | A | |
| $5.64 | A |
Be the first to know about important ASTH news, forecast changes, insider trades & much more!
ASTH News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASTH ($35.17) is undervalued by 58.93% relative to our estimate of its Fair Value price of $85.64 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ASTH ($35.17) is significantly undervalued by 58.93% relative to our estimate of its Fair Value price of $85.64 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ASTH ($35.17) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ASTH due diligence checks available for Premium users.
Valuation
ASTH fair value
Fair Value of ASTH stock based on Discounted Cash Flow (DCF)
Price
$35.17
Fair Value
$85.64
Undervalued by
58.93%
ASTH ($35.17) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ASTH ($35.17) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ASTH ($35.17) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ASTH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
26.85x
Industry
12.88x
Market
30.45x
ASTH is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ASTH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ASTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.81x
Industry
4.4x
ASTH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ASTH price to earnings growth (PEG)
For valuing profitable companies with growth potential
ASTH is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ASTH's financial health
Profit margin
Revenue
$478.7M
Net Income
$16.1M
Profit Margin
3.4%
ASTH's Earnings (EBIT) of $118.93M... subscribe to Premium to read more.
Interest Coverage Financials
ASTH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$778.3M
Debt to equity
1.11
ASTH's short-term assets ($596.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASTH's short-term assets ($596.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$34.0M
Investing
-$8.1M
Financing
-$3.2M
ASTH's operating cash flow ($82.45M)... subscribe to Premium to read more.
Debt Coverage Financials
ASTH vs Medical Care Facility Stocks
Astrana Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.